

DEINOVE STRENGTHENS ITS CORE TECHNOLOGY IN 2G ETHANOL THROUGH NEW KEY PATENTS

- **DEINOVE has been granted five new patents this year, including its first in China**
- **These patents protect the technological basis of the DEINOL process: degradation of lignocellulosic biomass and bioethanol production by *Deinococcus***

Montpellier, December 10, 2014 – DEINOVE (Alternext Paris: ALDEI), a cleantech company that designs and develops new industrial production standards based on the exploitation of *Deinococcus* bacteria, announces today the issuance of its first patent in China: the PF4 patent “Compositions and methods for degrading lignocellulosic biomass”¹.

Other four patents were issued to DEINOVE in 2014: the PF2 patent in Eurasia “Use of bacteria for the production of bioenergy”², the PF6 patent in Ukraine “Recombinant bacteria and the uses thereof for producing ethanol”³, and the PF8⁴ and PF9⁵ patents in South Africa related to the digestive enzymes of plant polymers. All these patents cover the basis of the DEINOL process in the production of 2G bioethanol.

The Company has built a unique portfolio of patents and innovative industrial bioprocesses based on *Deinococcus* bacteria. Today, it owns 183 international patent applications divided into 16 patent families including methods for microbial selection and identification, *Deinococcus* genetic engineering techniques, its unique capabilities, such as hydrolysing the lignocellulosic biomass, and its diverse industrial applications including the production of bioethanol and other bio-based compounds.

"We welcome the granting of these new patents addressing the degradation of the 2G biomass, and especially the patent issued in China. They help increase very significantly our panel of patents and geographical coverage. Intellectual property is obviously a major element of value creation in our markets", states Emmanuel Petiot, CEO of DEINOVE. He recalls that *"Unlike the microorganisms commonly used, Deinococcus offers a substantial range of opportunities to develop. Therefore, we have the considerable advantage of building global, exclusive, proprietary technology that will allow us to deliver high-performance bioproduction systems, economically viable and environmentally much more efficient."*

¹ WO 2010/094665

² WO 2009/063079

³ WO 2010/130806

⁴ WO 2012/062767

⁵ WO 2012/062768

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria's unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company's primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.

Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs over 40 people in its new offices and laboratories located in Montpellier, France.

More information at www.deinove.com

Contacts

DEINOVE

Emmanuel Petiot

CEO

Tel.: +33 (0) 4 48 19 01 28

emmanuel.petiot@deinove.com

Coralie Martin

Communication, Marketing and IR Manager

Tel.: +33 (0) 4 48 19 01 60

coralie.martin@deinove.com

ALIZE RP, Press Relations

Caroline Carmagnol

Mobile: +33 (0) 6 64 18 99 59

deinove@alizerp.com

